| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hypertension | D006973 | 115 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Wada Y et al. | Enamel matrix derivative neutralized the effect of lipopolysaccharide on osteoprotegerin and receptor activator of nuclear factor kappa B ligand expression of osteoblasts. | 2009 | Arch. Oral Biol. | pmid:19201394 |
| Park H and Yim M | Rolipram, a phosphodiesterase 4 inhibitor, suppresses PGE2-induced osteoclast formation by lowering osteoclast progenitor cell viability. | 2007 | Arch. Pharm. Res. | pmid:17489366 |
| Kim YH et al. | Dexamethasone inhibits the formation of multinucleated osteoclasts via down-regulation of beta3 integrin expression. | 2006 | Arch. Pharm. Res. | pmid:16964765 |
| Bandeira F et al. | Bone markers and osteoporosis therapy. | 2014 | Arq Bras Endocrinol Metabol | pmid:25166041 |
| Bennett BJ et al. | Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. | 2006 | Arterioscler. Thromb. Vasc. Biol. | pmid:16840715 |
| Koole D et al. | Osteoprotegerin is associated with aneurysm diameter and proteolysis in abdominal aortic aneurysm disease. | 2012 | Arterioscler. Thromb. Vasc. Biol. | pmid:22516062 |
| Moran CS et al. | Modulation of Kinin B2 Receptor Signaling Controls Aortic Dilatation and Rupture in the Angiotensin II-Infused Apolipoprotein E-Deficient Mouse. | 2016 | Arterioscler. Thromb. Vasc. Biol. | pmid:26966276 |
| Sandberg WJ et al. | Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. | 2006 | Arterioscler. Thromb. Vasc. Biol. | pmid:16424351 |
| Schoppet M et al. | RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. | 2002 | Arterioscler. Thromb. Vasc. Biol. | pmid:11950689 |
| Clancy P et al. | Assessment of a serum assay for quantification of abdominal aortic calcification. | 2006 | Arterioscler. Thromb. Vasc. Biol. | pmid:17053174 |
| Preusch MR et al. | Critical role of macrophages in glucocorticoid driven vascular calcification in a mouse-model of atherosclerosis. | 2008 | Arterioscler. Thromb. Vasc. Biol. | pmid:18787189 |
| Caidahl K et al. | Osteoprotegerin: a biomarker with many faces. | 2010 | Arterioscler. Thromb. Vasc. Biol. | pmid:20720194 |
| Semb AG et al. | Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. | 2009 | Arterioscler. Thromb. Vasc. Biol. | pmid:19325145 |
| Callegari A et al. | Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification. | 2013 | Arterioscler. Thromb. Vasc. Biol. | pmid:23990207 |
| Lieb W et al. | Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. | 2010 | Arterioscler. Thromb. Vasc. Biol. | pmid:20448212 |
| Price PA et al. | Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. | 2001 | Arterioscler. Thromb. Vasc. Biol. | pmid:11597934 |
| Moran CS et al. | Osteoprotegerin deficiency limits angiotensin II-induced aortic dilatation and rupture in the apolipoprotein E-knockout mouse. | 2014 | Arterioscler. Thromb. Vasc. Biol. | pmid:25301844 |
| Abedin M et al. | Vascular calcification: mechanisms and clinical ramifications. | 2004 | Arterioscler. Thromb. Vasc. Biol. | pmid:15155384 |
| Ovchinnikova O et al. | Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice--brief report. | 2009 | Arterioscler. Thromb. Vasc. Biol. | pmid:19592469 |
| Hagedorn C et al. | Identification and functional analyses of molecular haplotypes of the human osteoprotegerin gene promoter. | 2009 | Arterioscler. Thromb. Vasc. Biol. | pmid:19661483 |
| Dhore CR et al. | Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. | 2001 | Arterioscler. Thromb. Vasc. Biol. | pmid:11742876 |
| Orita Y et al. | Role of osteoprotegerin in arterial calcification: development of new animal model. | 2007 | Arterioscler. Thromb. Vasc. Biol. | pmid:17615383 |
| Jansson AM et al. | Multimarker risk assessment including osteoprotegerin and CXCL16 in acute coronary syndromes. | 2012 | Arterioscler. Thromb. Vasc. Biol. | pmid:23023373 |
| Gravallese EM et al. | The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. | 2001 | Arthritis Res. | pmid:11178122 |
| Schett G et al. | The role of osteoprotegerin in arthritis. | 2003 | Arthritis Res. Ther. | pmid:12932284 |
| Tat SK et al. | Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. | 2007 | Arthritis Res. Ther. | pmid:17996099 |
| MartÃnez-Calatrava MJ et al. | RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis. | 2012 | Arthritis Res. Ther. | pmid:22709525 |
| Dalbeth N et al. | Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. | 2010 | Arthritis Res. Ther. | pmid:20796300 |
| Findlay D et al. | Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. | 2008 | Arthritis Res. Ther. | pmid:18182105 |
| Kato G et al. | The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study. | 2015 | Arthritis Res. Ther. | pmid:26373710 |
| Stolina M et al. | RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. | 2009 | Arthritis Res. Ther. | pmid:20003323 |
| Audo R et al. | Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort. | 2015 | Arthritis Res. Ther. | pmid:26220665 |
| Nich C et al. | Oestrogen deficiency modulates particle-induced osteolysis. | 2011 | Arthritis Res. Ther. | pmid:21696618 |
| Kubota T et al. | NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. | 2007 | Arthritis Res. Ther. | pmid:17892600 |
| Carmona-Fernandes D et al. | Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients. | 2011 | Arthritis Res. Ther. | pmid:22027240 |
| Poubelle PE et al. | Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. | 2007 | Arthritis Res. Ther. | pmid:17341304 |
| D'Elia HF et al. | Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. | 2003 | Arthritis Res. Ther. | pmid:12823855 |
| Brabnikova-Maresova K et al. | Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis. | 2014 | Arthritis Res. Ther. | pmid:25280749 |
| Knevel R et al. | A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. | 2014 | Arthritis Res. Ther. | pmid:24886600 |
| Granet C et al. | Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. | 2004 | Arthritis Res. Ther. | pmid:15142264 |
| Juarranz Y et al. | Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. | 2005 | Arthritis Res. Ther. | pmid:16207319 |
| Görtz B et al. | Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo. | 2005 | Arthritis Res. Ther. | pmid:16207331 |
| Revu S et al. | Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate. | 2013 | Arthritis Res. Ther. | pmid:24295447 |
| Boyce BF and Xing L | Biology of RANK, RANKL, and osteoprotegerin. | 2007 | Arthritis Res. Ther. | pmid:17634140 |
| Crotti TN et al. | The immunoreceptor tyrosine-based activation motif (ITAM) -related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. | 2012 | Arthritis Res. Ther. | pmid:23146195 |
| Marotte H et al. | Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. | 2005 | Arthritis Res. Ther. | pmid:15642135 |
| Hofbauer LC and Heufelder AE | The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. | 2001 | Arthritis Rheum. | pmid:11229454 |
| Cohen S | Role of RANK ligand in normal and pathologic bone remodeling and the therapeutic potential of novel inhibitory molecules in musculoskeletal diseases. | 2006 | Arthritis Rheum. | pmid:16463406 |
| Haynes D et al. | Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome. | 2008 | Arthritis Rheum. | pmid:18576301 |
| Ziolkowska M et al. | High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. | 2002 | Arthritis Rheum. | pmid:12124857 |
| Campagnuolo G et al. | Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. | 2002 | Arthritis Rheum. | pmid:12124878 |
| Schett G et al. | Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. | 2003 | Arthritis Rheum. | pmid:12847699 |
| Marzaioli V et al. | Histamine contributes to increased RANKL to osteoprotegerin ratio through altered nuclear receptor 4A activity in human chondrocytes. | 2012 | Arthritis Rheum. | pmid:22674155 |
| Catrina AI et al. | Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. | 2006 | Arthritis Rheum. | pmid:16385498 |
| Hase H et al. | Coculture of osteoclast precursors with rheumatoid synovial fibroblasts induces osteoclastogenesis via transforming growth factor beta-mediated down-regulation of osteoprotegerin. | 2008 | Arthritis Rheum. | pmid:18975335 |
| Catrina AI and Klareskog L | Effects of disease-modifying antirheumatic drug treatment on the expression of RANKL and osteoprotegerin in synovial tissue: comment on the article by Haynes et al. | 2008 | Arthritis Rheum. | pmid:18975354 |
| Koufany M et al. | The peroxisome proliferator-activated receptor γ agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway. | 2013 | Arthritis Rheum. | pmid:23982996 |
| Tunyogi-Csapo M et al. | Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption. | 2008 | Arthritis Rheum. | pmid:18668542 |
| Kadri A et al. | Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. | 2008 | Arthritis Rheum. | pmid:18668550 |
| Takayanagi H et al. | Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. | 2000 | Arthritis Rheum. | pmid:10693864 |
| Rifas L and Weitzmann MN | A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. | 2009 | Arthritis Rheum. | pmid:19877052 |
| van Lent PL et al. | Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation. | 2006 | Arthritis Rheum. | pmid:17133594 |
| Dalle Carbonare L et al. | Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis. | 2009 | Arthritis Rheum. | pmid:19877060 |
| Schett G et al. | Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. | 2009 | Arthritis Rheum. | pmid:19714640 |
| Yang SY et al. | Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. | 2002 | Arthritis Rheum. | pmid:12355500 |
| Shimizu S et al. | Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. | 2007 | Arthritis Rheum. | pmid:17907189 |
| Lubberts E et al. | Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. | 2002 | Arthritis Rheum. | pmid:12428250 |
| Vandooren B et al. | The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. | 2008 | Arthritis Rheum. | pmid:18311801 |
| Loddenkemper K and Burmester GR | What is the rank of RANKL in spondylarthritis? | 2008 | Arthritis Rheum. | pmid:18311809 |
| Cho TJ et al. | Tumor necrosis factor alpha activation of the apoptotic cascade in murine articular chondrocytes is associated with the induction of metalloproteinases and specific pro-resorptive factors. | 2003 | Arthritis Rheum. | pmid:14558090 |
| Sanchez C et al. | Regulation of subchondral bone osteoblast metabolism by cyclic compression. | 2012 | Arthritis Rheum. | pmid:22034083 |
| Alvarez L et al. | Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. | 2003 | Arthritis Rheum. | pmid:12632438 |
| Kim JY et al. | Osteoprotegerin causes apoptosis of endothelial progenitor cells by induction of oxidative stress. | 2013 | Arthritis Rheum. | pmid:23666878 |
| Kim YG et al. | Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes. | 2010 | Arthritis Rheum. | pmid:20112365 |
| Moreno-Rubio J et al. | Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. | 2010 | Arthritis Rheum. | pmid:20112374 |
| Mosheimer BA et al. | Expression and function of RANK in human monocyte chemotaxis. | 2004 | Arthritis Rheum. | pmid:15248232 |
| Hughes C et al. | Human single-chain variable fragment that specifically targets arthritic cartilage. | 2010 | Arthritis Rheum. | pmid:20131274 |
| Schett G et al. | Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. | 2005 | Arthritis Rheum. | pmid:15880601 |
| Geusens PP et al. | The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. | 2006 | Arthritis Rheum. | pmid:16736519 |
| Geboes L et al. | Freund's complete adjuvant induces arthritis in mice lacking a functional interferon-gamma receptor by triggering tumor necrosis factor alpha-driven osteoclastogenesis. | 2007 | Arthritis Rheum. | pmid:17665444 |
| Lee CK et al. | Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. | 2004 | Arthritis Rheum. | pmid:15593184 |
| Neumann E et al. | The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. | 2005 | Arthritis Rheum. | pmid:16200575 |
| Redlich K et al. | Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. | 2002 | Arthritis Rheum. | pmid:11920416 |
| Makrygiannakis D et al. | Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. | 2006 | Arthritis Rheum. | pmid:16646024 |
| Balani D et al. | Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro. | 2013 | Arthritis Rheum. | pmid:23124514 |
| Komuro H et al. | The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. | 2001 | Arthritis Rheum. | pmid:11762937 |
| Mahoney DJ et al. | TSG-6 inhibits osteoclast activity via an autocrine mechanism and is functionally synergistic with osteoprotegerin. | 2011 | Arthritis Rheum. | pmid:21162099 |
| Audo R et al. | Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. | 2011 | Arthritis Rheum. | pmid:21305500 |
| Bolon B et al. | Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. | 2002 | Arthritis Rheum. | pmid:12483715 |
| Golmia RP et al. | Increased osteoprotegerin and decreased pyridinoline levels in patients with ankylosing spondylitis: comment on the article by Gratacós et al. | 2002 | Arthritis Rheum. | pmid:12483748 |
| Polzer K et al. | Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis. | 2011 | Arthritis Rheum. | pmid:21360496 |
| Oshita K et al. | Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production. | 2011 | Arthritis Rheum. | pmid:21360521 |
| Zwerina J et al. | Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. | 2004 | Arthritis Rheum. | pmid:14730626 |
| Koreny T et al. | The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. | 2006 | Arthritis Rheum. | pmid:17009257 |
| Brechter AB and Lerner UH | Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression. | 2007 | Arthritis Rheum. | pmid:17328065 |
| Kotake S et al. | Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. | 2001 | Arthritis Rheum. | pmid:11352231 |
| Rouster-Stevens KA et al. | RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. | 2007 | Arthritis Rheum. | pmid:17328075 |
| Jiang J et al. | LTB4 can directly stimulate human osteoclast formation from PBMC independent of RANKL. | 2005 | Artif Cells Blood Substit Immobil Biotechnol | pmid:16317958 |
| Bilgin E et al. | Markers of bone metastases in breast and lung cancers. | 2012 | Asian Pac. J. Cancer Prev. | pmid:23167338 |
| Chen T et al. | High throughput screening identified a substituted imidazole as a novel RANK pathway-selective osteoclastogenesis inhibitor. | 2006 | Assay Drug Dev Technol | pmid:16945012 |